VNDA · Vanda Pharmaceuticals Inc.
$5.16
-0.06 (-1.15%)
At close · Jul 28
Market Cap
$313.91M
Shares
60.14M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.16
Open$5.20
Day$5.08–5.25
52W$4.14–9.94
Avg vol 30d899K
Short int7.2M · 12.0% float · 8.8d
Short vol54%
Last earningsMay 6, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 7
Up next
Next earnings call
Aug 2, 2026
Est · unconfirmed
· in 1 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−21%
below
Price vs 50-day avg
−14%
below
RSI (14)
31
neutral
MACD trend
Negative
52-week position
18%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−14%
trailing
6-month return
−33%
trailing
YTD return
−42%
this year
Relative strength
−41%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
26 of 169 funds reported for Jun 30 · net +391.7K sh shares · +5 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
11.95% of float · ▼ -2.1% MoM · 8.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
169 holders — mid 3-yr range
Squeeze score
71
high risk · 0–100
Fundamentals
Revenue growth
+9%
Y/Y
Gross margin
28%
expanding
EPS growth
−1033%
Y/Y
Free cash flow
$-110.4M
Balance sheet
$84.9M
net cash
Quant / Vol
risk profile
Volatility
82%
annualized · 1-yr
Max drawdown
−46%
past year
ATR
4.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 6, 2026
Full-year 2026 revenue
· Full-year 2026
Maintained
$240M – $290M
prior FY $216.11M
midpoint +22.6% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−21%
Bearish
Price vs 50-day avg
−14%
Bearish
RSI (14)
31
Neutral
MACD trend
Negative
Bearish
52-week position
18%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $6 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
26 of 169 funds reported for Jun 30 · net +391.7K sh shares · +5 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
11.95% of float · ▼ -2.1% MoM · 8.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
169 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $4
Now $5 · 18%
52-wk high $10
vs 200-day avg -21%
vs 50-day avg -14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Fanapt® weekly TRx (week ending April 24, 2026) | 2,600 | week ending April 24, 2026 | — |
| Non-GAAP effective tax rate non-GAAP | 23% | Twelve Months Ended December 31, 2025 | — |
| Non-GAAP net loss per share, diluted non-GAAP | -$1.81 | Twelve Months Ended December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VNDA
this stock
Vanda Pharmaceuticals Inc.
|
$313.91M | -41.5% | -24.3% | — | 12.0% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.3% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.57B | +8.2% | +46.2% | 28.4 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.95B | -9.8% | +20.8% | 16.3 | 3.3% |
|
ARGX
Argenx SE
|
$55.61B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VNDA | -3.0% | -14.1% | -33.3% | -15.7% | -41.5% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -2.0% | -14.1% | -40.8% | -14.9% | -50.1% |
Key facts
CIK
1347178
CUSIP
921659108
13F (30d)
27 filings
27 filers
Visit website
Investor relations